all updates

Press Releases

MDS Hub Press Release Q1: The MDS Hub Continues To Enhance Global Knowledge Of Myelodysplastic Syndromes Throughout Through Key Congress Coverage In 2022

April 13, 2022

The MDS Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in myelodysplastic syndromes (MDS). During Q1 of 2022, the MDS Hub continued to share latest advancements related to MDS, including updates from ongoing clinical trials and information on cutting-edge discoveries in treatments and therapeutic regimens. 

In March, the MDS Hub provided extensive coverage of the 48th Annual Meeting of the EBMT through live social media updates, expert interviews, and summary articles. This coverage contributed to the hub receiving over 7,200 views and 1,200 visitors during Q1. The impact of our coverage on social media was also evident, with our social channels receiving over 20,000 impressions during the quarter. 

During Q1 of 2022, we also produced two visual abstracts: the first presented key data from a study evaluating lenalidomide and eltrombopag for treating symptomatic anemia in patients with low- or intermediate-risk MDS; and the second summarized data from the AZALENA trial, investigating azacitidine, lenalidomide, and donor lymphocyte infusion as salvage therapy for MDS, chronic myelomonocytic leukemia, and secondary AML after allo-HSCT. 

Reviewing the MDS Hub’s impact this quarter, Claire Aukim-Hastie, Director of Scientific Services, Scientific Education Support, said: 

“During this quarter, we attended the 48th Annual Meeting of the EBMT and updated our audience with advancements in the field of MDS. Some of the key areas that we covered included autologous immune cells in cellular therapy, protective donor genotypes, graft-versus-host disease, conditioning, and pediatrics. Our comprehensive coverage gives those who are unable to attend the conference instant updates and key insights into the latest research and treatment methods for MDS. 

“As part of our commitment to continuously enhance the hub’s user experience, we have introduced new digital innovations, including learning objectives and interactive quizzes to test a user’s knowledge before and after viewing our content. We have also updated the hub with Google Translate, and as a result, the hub’s content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences. 

“We would like to take this opportunity to show our gratitude for our expert steering committee and existing supporters—Novartis, Bristol Myers Squibb, Janssen Oncology, Geron, and Takeda—without whom this continued activity would not be possible.” 


For more information on the MDS Hub, please visit

For media enquiries, or to explore collaboration opportunities, please contact or

About myelodysplastic syndromes (MDS) 

Myelodysplastic syndromes (MDS) refer to a group of hematopoietic disorders that result in the production of insufficient numbers of healthy blood cells, along with changes in bone marrow morphology and, eventually, overall failure of the bone marrow. Progression of MDS can be indolent or aggressive, and some patients may go on to develop acute myeloid leukemia. 

About the MDS Hub 

The MDS Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MDS. Our aim is to enhance knowledge of MDS through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. 

The MDS Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the MDS Hub supports HCPs worldwide. 

Founded in partnership with the European LeukemiaNet (ELN) in 2020, the MDS Hub is guided by an international steering committee of experts in the field of MDS. The steering committee meet regularly to discuss the performance of the MDS Hub and to devise action plans on how best to support the MDS community and address any unmet educational needs. 

MDS Hub supporters 

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content. 

  • Novartis 
  • Bristol Myers Squibb 
  • Geron 
  • Takeda 
  • Janssen Oncology 

If you are interested in becoming an MDS Hub supporter, please contact

About Scientific Education Support (SES) 

SES is a medical education company with projects such as community physician education though our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs. 

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, Multiple Myeloma Hub, and MPN Hub

About the European LeukemiaNet 

220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia. 

Sign Up For Our Monthly Newsletter

Looking to receive the latest news, project updates, and new offerings?